Developing vaccines for glioblastoma remains challenging owing to the immunosuppressive microenvironment of the tumour and the presence of the blood–brain barrier. In this Perspective, we explore how nanomaterials can be tailored to address the limitations of glioblastoma vaccination, potentially paving the way for important advancements.
- Fatima Hameedat
- Bárbara B. Mendes
- Flávia Sousa